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evidence were extracted. Results: Our search identified 19 submissions, all of 
which included a placebo-controlled trial, and all except dimethyl fumarate also 
included a head-to-head trial against one of the beta-interferons but not any other 
therapies. Indirect comparisons against old and newer DMTs were also included 
in the submissions. Approximately 90% of appraisals received positive recom-
mendations; reasons for positive recommendations included recognition that 
there is a need for additional treatment options in MS, particularly for patients 
who do not have an adequate response to beta-interferons, and that oral DMTs 
represent an innovative step in the treatment of MS. However, submissions were 
generally criticised for trial design, scarcity of head-to-head trials, use of EDSS 
to measure disability, the uncertainty regarding long-term clinical and economic 
outcomes, and the heterogeneity of trial populations included in indirect compari-
sons. ConClusions: Due to the changing treatment landscape and the popula-
tion included in MS trials, it is clear that placebo-controlled trials and the inclusion 
of beta-interferon trials in indirect comparisons are becoming less suitable for the 
evaluation of new MS treatments. Future HTA submissions will need to take into 
account the need to demonstrate superiority over comparators, and manufactur-
ers and regulators will need to work together to develop new and reliable measures 
that can evaluate MS symptoms and impairments in the context of DMTs.
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objeCtives: Health technology assessment and decision making process lean 
on evidences provided by RCTs. Our aim was to compare the characteristics of 
Hungarian patients with multiple sclerosis to the participants enrolled in pivotal 
trials of first-line DMTs. Methods: The database of the National Health Insurance 
Fund was used for analyze the attributes of all MS patients starting first-line DMTs 
between 2008 and 2013. We investigated the following characteristics: 1. age, 2. 
gender ratio, 3. time since first MS symptoms, 4. time since first MS diagnosis, 
5. number of relapses in 2 years prior to therapy. For the comparison we summarized 
phase III RCTs of interferon beta-1a and 1b, glatiramer-acetate, teriflunomide and 
dimethyl-fumarate. Results: A total of 3877 Hungarian MS patients were involved 
and 1670 were selected for analysis after excluding the population of the year of 
DMT inclusion. The mean age was 36.18±9.96 years which resembles to the par-
ticipants of old immunomodulatory drugs (≈36 years) and slightly younger than 
the patients of the trials with new therapies (≈38 years). There was no difference 
in gender ratio (≈70% female). While in the RCTs the mean time since first symp-
toms was longer than the mean time since first diagnosis (≈7–8 vs ≈5.5 years), in 
the Hungarian patients these two values did not differ significantly (3.30±3.80 vs 
3.17±3.77 years). We suspect that the reason for this unexpected difference can be 
explained by the imprecise use of ICD codes in Hungarian clinical practice. The 
relapse rate per 2 years seemed to decline in trials of the last two decades from 3 to 
2-2.5 which is equal to the Hungarian patients. ConClusions: The population of 
RCTs represents the Hungarian MS patients in certain aspects but not completely. 
Our analysis can help the adaptation of international models to local circumstances 
in HTA of forthcoming MS therapies.
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objeCtives: Disease Modifying Treatments (DMTs) to manage Relapsing Remitting 
Multiple Sclerosis (RRMS) patients have traditionally been injectables. With the 
introduction of new oral DMTs, a better understanding of the shift in treatment 
patterns and their impact on patient disease burden is needed. The objective of 
this study was to assess the characteristics of RRMS patients taking injectable 
and oral DMTs in the United States (US). Methods: A multi-center retrospective 
chart-review study of RRMS patients was conducted in the US in 4Q2013 to collect 
de-identified data on diagnosis, clinical status, and treatment patterns. Physicians 
were screened for duration of practice (≥ 3yrs) and patient volume (≥ 15 MS patients/
mo and recruited from a large panel to be geographically representative. Medical 
charts of the next 10 consecutive MS patients were abstracted. RRMS patients taking 
an injectable (INJ) or oral DMT were analyzed. Results: 561 eligible RRMS patients 
were included in the analysis (INJ: 66%; Oral: 34%). Patient characteristics were (INJ/
Oral): age: 41/40yrs, female: 71%/70%, time since diagnosis: 62/53mo, time between 
diagnosis and initiation of first DMT: 5/3mo, percent on first, second, and third line 
DMT were (INJ/Oral): 78%/30%, 18%/45%, and 4%/25%; time on current DMT (INJ/
Oral): 47mo/6mo. Reasons for current DMT initiation included (INJ/Oral): efficacy 
against relapses (32%/27%)/efficacy in slowing progression (24%/23%)/efficacy in 
early MS (21%/4%)/patient decision (7%/17%)/oral administration (0%/17%). Patient 
JCV status (INJ/Oral): positive-3%/23% & not tested-75%/46%; number of gadolinium-
enhanced & T2 lesions: 0.8/1.3 & 7.7/10.3; percent with ≥ 1 relapse in past 12mo: 
42%/66%; percent with Expanded Disability Status Scale score of ≥ 4.5: 15%/31%; 
percent with moderate-to-severe disability per physician judgment: 22%/40%; per-
cent with active or highly active disease per physician judgment: 37%/60%; percent 
with moderate-to-severe disease per physician judgment: 22%/44%. ConClusions: 
In this cohort of RRMS patients, physicians initiated oral DMTs predominantly as 
second or third-line treatment, and these patients may have higher disease bur-
den compared to those receiving injectable DMTs. Further research is needed to 
evaluate the observed treatment patterns and treatment sequencing strategies to 
alleviate patient burden.
(6.4%). ConClusions: These data suggest that, after initial monotherapy, a major-
ity of epilepsy treatment decisions do not follow 2012 NICE guidelines, with the 
degree of divergence increasing through lines of therapy. These results call for more 
detailed investigation into treatment patterns and the reasons for divergence from 
clinical guidelines in epilepsy.
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objeCtives: Progression of symptoms among Relapsing Remitting Multiple 
Sclerosis (RRMS) patients may necessitate active disease management. The objective 
of the study was to assess the patterns of use of tests to monitor disease activity/
progression in RRMS in EU and US, based on disease severity. Methods: A multi-
center retrospective chart-review study of MS patients was conducted in EU (UK/
France/Germany/Italy/Spain) and US to collect de-identified data on diagnosis, clini-
cal status, and disease management approaches. Health care providers (HCPs; 94% 
neurologists) were screened for duration of practice (≥ 3yrs) and patient volume (≥ 15 
MS patients/mo) and recruited from a large panel to be geographically representative 
in each country. Medical charts of next 10 consecutive MS patients were abstracted 
by each HCP. RRMS patient data was analyzed. Results: 2433 eligible RRMS patient 
charts were abstracted by 365 HCPs (EU/US: N= 265/100; mean neurology practice 
duration= 17/21yrs; mean number of patients seen per month= 66/62). In EU/US, 
patient mean age: 37/41yrs, female: 67%/70%, currently treated: 85%/88%, currently 
with mild: moderate: severe disease-60%: 34%: 5%/67%: 29%: 3%. Top-5 tests used 
to monitor RRMS varied between the regions overall as well as by patient disease 
severity (EU/US: %patients): Neurological exam: overall-83/88, mild-80/89, moder-
ate-87/86, severe-91/90; Gadolinium MRI: overall-62/71, mild-57/71, moderate-69/71, 
severe-77/70; T2 MRI: overall-62/73, mild-59/74, moderate-66/70, severe-64/75; T1 
MRI: overall-53/62, mild-51/64, moderate-55/58, severe-59/70; Expanded Disability 
Status Scale (EDSS): overall-86/29, mild-87/29, moderate-86/30, severe-80/35. 
Percent with unknown Gd-enhanced lesions were (EU/US): overall-33/40, mild-
37/42, moderate-29/37, severe-17/25. Percent with unknown T2 lesions were (EU/
US): overall-33/35, mild-34/36, moderate-32/34, severe-17/20. UK HCPs reported 
substantially more patients with unknown Gd-enhanced (70%) and T2 lesions 
(66%). ConClusions: Besides neurological exam and EDSS, MRI testing is widely 
used and its use increased with increasing disease severity (EU only); the percent 
of patients with unknown lesions decreased correspondingly. Still, one-third of 
patients had unknown lesions (with UK reporting two-thirds), warranting further 
scrutiny on practice patterns and diagnostics to optimize available therapeutic 
choices and alleviate disease burden.
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objeCtives: The aim of our study is to assess amount and frequency of the physi-
otherapy services in the different neurology diseases within out-patient care in 
Hungary. Methods: The data come from the nationwide, financial data base of 
the National Health Insurance Fund Administration covering the official reports 
of outpatient care institutes in 2009. The total numbers of different physiotherapy 
services were determined by selecting the reported specific diagnoses codes and 
counting the number treatments provided for that specific diagnosis code. The dis-
eases of the nervous system are listed in the International Classification of Diseases 
(ICD) with code of G00-G99. Results: The total number of the 151 different types 
WHO-classified physiotherapy procedures was 32318413; and 1331675 (4.12%) of 
them related to neurology care with the ICD code group G00-G99. The amount and 
frequency of the physiotherapy services are in the different neurology diseases are 
the following: Inflammatory diseases of the central nervous system 3584 (0.26%), 
Systemic atrophies primarily affecting the central nervous system 7265 (0.52%), 
Extrapyramidal and movement disorders 82923 (5.96%), Other degenerative diseases 
of the nervous system 15717 (1.13%), Demyelinating diseases of the central nervous 
system 30300 (2.18%), Episodic and paroxysmal disorders 191909 (13.80%), Nerve, 
nerve root and plexus disorders 438780 (31.56%), Polyneuropathies and other disor-
ders of the peripheral nervous system 96871 (6.97%), Diseases of myoneural junction 
and muscle 21276 (1.53%), Cerebral palsy and other paralytic syndromes 434550 
(31.26%), Other disorders of the nervous system 67024 (4.82%). ConClusions: The 
diseases of the nervous system showed different utilization frequency in physi-
otherapy services and represent a significant burden for the health care system.
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objeCtives: In recent years, a number of new DMTs for the treatment of MS 
have been approved by the FDA and EMA, specifically fingolimod, dimethyl 
fumarate, teriflunomide, and alemtuzumab. This study evaluated the HTA 
appraisals for these DMTs to identify any trends or future opportunities in 
MS. Methods: HTA appraisals for fingolimod, dimethyl fumarate, terifluno-
mide, and alemtuzumab from NICE (England), SMC (Scotland), CADTH (Canada), 
PBAC (Australia), HAS (France), TLV (Sweden) and IQWiG (Germany) were iden-
tified. Recommendations, reasoning, and the supporting clinical and economic 
